| Fri, Apr 3, 2009 | | • | Arzerra(tm) (ofatumumab) Granted Priority Review by FDA
GlobeNewswire (Fri, Apr 3)
| | Wed, Mar 25, 2009 | | • | Genmab A/S Summons Annual General Meeting
GlobeNewswire (Wed, Mar 25)
| | Thu, Feb 26, 2009 | | • | Arzerra(TM) (ofatumumab) MAA Accepted by EMEA
GlobeNewswire (Thu, Feb 26)
| | Tue, Feb 24, 2009 | | • | Genmab Announces Year End 2008 Financial Results
GlobeNewswire (Tue, Feb 24)
| | Thu, Feb 5, 2009 | | • | GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
GlobeNewswire (Thu, Feb 5)
| | Mon, Jan 5, 2009 | | • | Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer
GlobeNewswire (Mon, Jan 5)
| | Thu, Dec 18, 2008 | | • | Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline
GlobeNewswire (Thu, Dec 18)
| | Wed, Dec 10, 2008 | | • | Genmab's Financial Calendar for 2009
GlobeNewswire (Wed, Dec 10)
| | Mon, Dec 8, 2008 | | • | Genmab A/S: Arzerra(TM) (Ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukaemia (CLL)
GlobeNewswire (Mon, Dec 8)
|
Add GEN News to My Yahoo!:
 
| |
|
0.22% Nasdaq 
Headlines
